近日，美国FDA批准Pazeo（olopatadine hydrochloride）用于与过敏性结膜炎相关眼部瘙痒治疗。Pazeo（olopatadine hydrochloride）是每天使用一次的一种滴眼液，在两项研究中，该滴眼液证明Pataday(olopatadine hydrochloride) 滴眼液0.7%治疗24小时后疾病能得到统计学意义上的明显改善性缓解。
批准日期：2015年01月29日 公司：爱尔康
PAZEO（盐酸奥洛他定[olopatadine hydrochloride]）滴眼液0.7％，用于局部眼科给药。
美国初次批准：1996年
作用机理
奥洛他定是肥大细胞稳定剂和组胺H1拮抗剂。 还已经证实趋化性降低和嗜酸性粒细胞活化的抑制。
适应症和用途
PAZEO是肥大细胞稳定剂，可用于治疗与过敏性结膜炎有关的眼痒。
剂量和给药
建议剂量是每天每只受影响的眼睛滴一滴。
剂量形式和强度
滴眼液：在4毫升瓶中的1毫升溶液（0.7％）中加入7.76毫克的盐酸奥洛他定。
禁忌症
没有。
警告和注意事项
尖端和溶液污染。 为防止污染滴管尖端和溶液，请勿用瓶的滴管尖端接触眼睑或周围区域。
不良反应
最常见的不良反应（2-5％）是视力模糊，浅点状角膜炎，干眼症，眼部异常感觉和消化不良。
包装供应/存储和处理方式
0.7％的PAZEO（盐酸奥洛他定滴眼液）采用白色，椭圆形，低密度聚乙烯DROP-TAINER*分配器提供，该分配器带有天然的低密度聚乙烯分配塞和白色聚丙烯盖。包装的颈部区域。PAZEO装在一个4 mL的瓶子中，该瓶子中含有2.5mL盐酸奥洛他定眼用溶液[在1mL溶液中含有7.76mg盐酸奥洛他定（0.7％）]。
NDC 0065-4273-25
存放：存放在2°C至25°C（36°F至77°F）。不使用时，请保持瓶子密闭。
完整资料附件： https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13c52523-32ad-b865-eeaa-56b301151779 PAZEO (olopatadine hydrochloride ophthalmic solution) 0.7%
For topical ophthalmic administration.
Initial U.S. Approval: 1996
INDICATION AND DOSING
PAZEO® Solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis. The recommended dosage is to instill one drop in each affected eye once a day.
IMPORTANT SAFETY INFORMATION
As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle to prevent contaminating the tip and solution. Keep bottle tightly closed when not in use.
Patients should not wear a contact lens if their eye is red. PAZEO® Solution should not be used to treat contact lens-related irritation. The preservative in PAZEO® Solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least five minutes after instilling PAZEO® Solution before they insert their contact lenses.
The most commonly reported adverse reactions in a clinical study occurred in 2%-5% of patients treated with either PAZEO® Solution or vehicle. These events were blurred vision, dry eye, superficial punctate keratitis, dysgeusia, and abnormal sensation in eye.
